Contactez-nous

Sociétés CDMO Leaders en Chine

Vos Partenaires de Confiance en Chine pour la Fabrication et le Développement sous Contrat.

Showing 14 facilities
Pharmaron API Commercial Synthesis Shaoxing (China)
Chine

Pharmaron API Commercial Synthesis Shaoxing (China)

Pharmaron

Synthèse commerciale de petites molécules/peptides API.

TAILLE DU LOT: Petit, Moyen, Grandes dimensions

DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (R) Respiratory system, (V09-10) Radiopharmaceuticals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (G) Genito urinary system and sex hormones, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (B) Blood and blood forming organs, (V06) Nutrients

USAGE: Humain, Vétérinaire

SERVICES: Analytical / QC services, Manufacturing services, Regulatory services, Development services, Quality Assurance services

RÉGION: Asie-Pacifique

OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/jour), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)

MARCHÉS: FDA (USA), NMPA (China)

COMPLIANCE: FDA (cGMP), NMPA (BPF de Chine), ISO

CATÉGORIE / PRODUIT: CHIMIQUE-SYNTHÉTIQUE

CARBOGEN AMCIS | Shanghai, China
Chine

CARBOGEN AMCIS | Shanghai, China

CARBOGEN AMCIS

Fabrication à grande échelle.

MARCHÉS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), Rest of World, ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

TAILLE DU LOT: Petit, Moyen, Grandes dimensions

DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (R) Respiratory system, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (B) Blood and blood forming organs, (V06) Nutrients

CATÉGORIE / PRODUIT: SERVICES, OLIGONUCLÉOTIDES, CHIMIQUE-SYNTHÉTIQUE

USAGE: Humain

COMPLIANCE: ANVISA (Brazil B-GMP), NMPA (BPF de Chine)

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services

RÉGION: Asie-Pacifique

OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/jour), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)

Apeloa Pharmaceutical Co., Ltd.
Chine

Apeloa Pharmaceutical Co., Ltd.

Apeloa Pharmaceutical Co., Ltd

Apeloa CDMO fournit des services de découverte, de développement et de fabrication de classe mondiale pour les API, les intermédiaires et les RSM.

MARCHÉS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

TAILLE DU LOT: Petit, Moyen, Grandes dimensions

COMPLIANCE: EMA (BPF DE L'UE), PMDA/MHLW (Japan GMP), Organisation mondiale de la santé (BPF / HACCP), FDA (cGMP), NMPA (BPF de Chine), ECOVADIS, ISO

USAGE: Humain, Vétérinaire

SERVICES: Analytical / QC services, Manufacturing services, Regulatory services, Development services, Packaging

RÉGION: Asie-Pacifique

OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/jour), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)

CATÉGORIE / PRODUIT: CHIMIQUE-SYNTHÉTIQUE

Sichuan Huiyu Pharmaceuticals Co., Ltd. - API Manufacturing Site
Chine

Sichuan Huiyu Pharmaceuticals Co., Ltd. - API Manufacturing Site

Seacross Pharmaceutical Co Ltd

En tant que l'un des trois sites principaux, aux côtés du centre de R&D et de l'usine de formulation, notre usine de fabrication d'API joue un rôle essentiel da

MARCHÉS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), Rest of World, ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

TAILLE DU LOT: Petit, Moyen, Grandes dimensions

DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (R) Respiratory system, (V09-10) Radiopharmaceuticals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (G) Genito urinary system and sex hormones, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (B) Blood and blood forming organs, (V06) Nutrients

COMPLIANCE: ISP (Chile BPM), Roszdravnadzor (Russia GMP), ANMAT (Argentine nouveau GMP), EMA (BPF DE L'UE), PMDA/MHLW (Japan GMP), IFS, DIGEMID, UAE Ministry of Health & Prevention, ANVISA (Brazil B-GMP), Organisation mondiale de la santé (BPF / HACCP), MHRA (BPF AU ROYAUME-UNI), Service public français (CIR), TGA (Australia GMP), FDA (cGMP), NSF, NMPA (BPF de Chine), SFDA (Saudi Food & Drug Authority), BRCGS, ECOVADIS, ISO, Conseil de recherche sur le halal, INVIMA, Santé Canada (Canada GMP), SQF (Safe Quality Food), TITCK (Turkish Health Authorities), MSPAS, MFDS/KFDA (République de Corée GMP), COFEPRIS

SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse

BSL (niveau de sécurité biologique): 3, 4, 1, 2

USAGE: Humain

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services

RÉGION: Asie-Pacifique

OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/jour), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)

CATÉGORIE / PRODUIT: CHIMIQUE-SYNTHÉTIQUE

Sichuan Huiyu Pharmaceuticals Co., Ltd. - R&D Site
Chine

Sichuan Huiyu Pharmaceuticals Co., Ltd. - R&D Site

Seacross Pharmaceutical Co Ltd

Le centre de R&D joue un rôle fondamental en soutenant le développement d’API et de formes posologiques finies.

MARCHÉS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), Rest of World, ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

TAILLE DU LOT: Petit, Moyen, Grandes dimensions

DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (R) Respiratory system, (V09-10) Radiopharmaceuticals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (G) Genito urinary system and sex hormones, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (B) Blood and blood forming organs, (V06) Nutrients

CATÉGORIE / PRODUIT: FDF / PRODUITS MÉDICAMENTEUX, CHIMIQUE-SYNTHÉTIQUE

COMPLIANCE: ISP (Chile BPM), Roszdravnadzor (Russia GMP), ANMAT (Argentine nouveau GMP), EMA (BPF DE L'UE), PMDA/MHLW (Japan GMP), IFS, DIGEMID, UAE Ministry of Health & Prevention, ANVISA (Brazil B-GMP), Organisation mondiale de la santé (BPF / HACCP), MHRA (BPF AU ROYAUME-UNI), Service public français (CIR), TGA (Australia GMP), FDA (cGMP), NSF, NMPA (BPF de Chine), SFDA (Saudi Food & Drug Authority), BRCGS, ECOVADIS, ISO, Conseil de recherche sur le halal, INVIMA, Santé Canada (Canada GMP), SQF (Safe Quality Food), TITCK (Turkish Health Authorities), MSPAS, MFDS/KFDA (République de Corée GMP), COFEPRIS

SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse

BSL (niveau de sécurité biologique): 3, 4, 1, 2

USAGE: Humain

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services

RÉGION: Asie-Pacifique

OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/jour), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)

Sichuan Huiyu Pharmaceuticals Co., Ltd. - Formulation Manufacturing Site
Chine

Sichuan Huiyu Pharmaceuticals Co., Ltd. - Formulation Manufacturing Site

Seacross Pharmaceutical Co Ltd

Le site de fabrication de formulations est dédié au développement et à la production de formes galéniques complexes et de grande valeur.

MARCHÉS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), Rest of World, ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

TAILLE DU LOT: Petit, Moyen, Grandes dimensions

DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (R) Respiratory system, (H) Systemic hormonal preparations excl. sex hormones and insulins, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (G) Genito urinary system and sex hormones, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (B) Blood and blood forming organs, (V06) Nutrients

CATÉGORIE / PRODUIT: FDF / PRODUITS MÉDICAMENTEUX, SERVICES

COMPLIANCE: ISP (Chile BPM), Roszdravnadzor (Russia GMP), ANMAT (Argentine nouveau GMP), EMA (BPF DE L'UE), PMDA/MHLW (Japan GMP), IFS, DIGEMID, UAE Ministry of Health & Prevention, ANVISA (Brazil B-GMP), Organisation mondiale de la santé (BPF / HACCP), MHRA (BPF AU ROYAUME-UNI), Service public français (CIR), TGA (Australia GMP), FDA (cGMP), NSF, NMPA (BPF de Chine), SFDA (Saudi Food & Drug Authority), BRCGS, ECOVADIS, ISO, Conseil de recherche sur le halal, INVIMA, Santé Canada (Canada GMP), SQF (Safe Quality Food), TITCK (Turkish Health Authorities), MSPAS, MFDS/KFDA (République de Corée GMP), COFEPRIS

SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse

BSL (niveau de sécurité biologique): 3, 4, 1, 2

USAGE: Humain

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services

RÉGION: Asie-Pacifique

OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/jour), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)

Limited view

CDMO/CMO facility

MAI network supplier

Services B2B de R&D et OEM/ODM sur les peptides pour les marques et les fabricants de cosmétiques.

Location available after registration

Limited view

CDMO/CMO facility

MAI network supplier

Services B2B de R&D et OEM/ODM sur les peptides pour les marques et les fabricants de cosmétiques.

Location available after registration

Limited view

FDF / PRODUITS MÉDICAMENTEUX manufacturing site

MAI network supplier

Solutions CDMO à guichet unique pour les APL et les intermédiaires clés.

Location available after registration

Suggested Results

These facilities match your main criteria but not all optional filters.

SENN India | Non-GMP Plant | Hyderabad, India
Inde

SENN India | Non-GMP Plant | Hyderabad, India

Senn Chemicals

Site de fabrication non BPF à grande échelle pour les intermédiaires peptidiques, la synthèse organique, les opérations LPPS et l'augmentation de la production.

TAILLE DU LOT: Petit, Moyen, Grandes dimensions

CATÉGORIE / PRODUIT: COSMETICS, SERVICES, INGÉNIERIE DES PARTICULES, CHIMIQUE-SYNTHÉTIQUE

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services

RÉGION: Asie-Pacifique

SENN India | R&D Lab | Hyderabad, India
Inde

SENN India | R&D Lab | Hyderabad, India

Senn Chemicals

Centre de R&D pour la chimie peptidique et organique avec support SPPS, purification, lyophilisation, analyse et ingénierie des particules.

TAILLE DU LOT: Petit

SERVICES: Analytical / QC services, Logistics, Development services, Packaging, Quality Assurance services

RÉGION: Asie-Pacifique

CATÉGORIE / PRODUIT: INGÉNIERIE DES PARTICULES, CHIMIQUE-SYNTHÉTIQUE

Viswa Laboratories Pvt Ltd
Inde

Viswa Laboratories Pvt Ltd

Viswa Laboratories Private Limited

CRAMS/CDMO, API, intermédiaires et produits chimiques de spécialité.

TAILLE DU LOT: Petit, Moyen, Grandes dimensions

DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (R) Respiratory system, (M) Musculoskeletal system, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (D) Dermatologicals

SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, Lower potential for abuse, Low potential for abuse

MARCHÉS: ANVISA (Brazil), CDSCO (India), Russian Health Authorities, EMA (EU), NMPA (China)

USAGE: Humain, Vétérinaire

COMPLIANCE: Organisation mondiale de la santé (BPF / HACCP)

RÉGION: Asie-Pacifique

OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)

SERVICES: Manufacturing services, Development services

BSL (niveau de sécurité biologique): 1, 2

CATÉGORIE / PRODUIT: CHIMIQUE-SYNTHÉTIQUE

More facilities on the network

Register to unlock the full catalog with contact details and locations.

+5 more facilities

Create free account

China has emerged as a global powerhouse for Contract Development and Manufacturing Organizations (CDMOs) in the pharmaceutical industry. CDMOs in China and pharmaceutical CDMO China services offer comprehensive solutions from drug development to large-scale commercial manufacturing, helping biotech companies and pharmaceutical firms worldwide bring innovative therapies to market efficiently and cost-effectively.


Why Choose CDMO Companies in China?

China CDMO providers and pharmaceutical manufacturing China facilities are renowned for their cutting-edge technology, world-class infrastructure, and highly competitive pricing. Leading CDMO China companies specialize in handling various dosage forms including oral solids, injectables, biologics, and complex formulations like lyophilized products and sustained-release formulations. Most Chinese CDMO facilities maintain certifications from global regulatory bodies including FDA, EMA, PMDA, and WHO, ensuring full compliance across preclinical, clinical, and commercial manufacturing phases.

China´s strategic geographic location and advanced infrastructure provide exceptional access to global markets, with efficient pharmaceutical supply chain China logistics ensuring smooth operations and rapid distribution. With substantial government investment in pharmaceutical innovation China, Chinese CDMOs are equipped to handle even the most complex pharmaceutical development projects.


Key Services Offered by CDMOs in China

Drug Development Services China: Comprehensive formulation development, analytical method development and validation, process optimization, and scale-up services to ensure stable, scalable pharmaceutical products.

Pharmaceutical Manufacturing China: High-volume production capabilities across multiple formats including tablets, capsules, injectables, semi-solids, and biologics, providing flexible, high-quality manufacturing solutions.

API Manufacturing China: Extensive expertise in Active Pharmaceutical Ingredient synthesis, process development, and commercial-scale API manufacturing with strict quality control.

Regulatory Support China: Complete assistance with regulatory filings, NMPA (National Medical Products Administration) submissions, and compliance with FDA, EMA, and other international regulatory requirements.

Pharmaceutical Packaging China: Comprehensive primary and secondary packaging services including blister packaging, vial filling, and customized packaging solutions meeting global regulatory standards.


Advantages of Partnering with Chinese CDMO Companies

Cost-Effective Manufacturing China: China CDMO providers offer significant cost advantages without compromising quality, with manufacturing costs typically 30-50% lower than Western counterparts while maintaining international quality standards.

Advanced Facilities China: Modern pharmaceutical facilities China feature state-of-the-art equipment including continuous manufacturing systems, advanced aseptic processing, and high-containment manufacturing capabilities.

Regulatory Expertise China: Extensive experience with China NMPA regulations plus deep understanding of FDA, EMA, and other international regulatory requirements for global market access.

Technical Expertise China: Highly skilled scientific and technical workforce with strong capabilities in complex chemistry, biologics manufacturing, and advanced drug delivery systems.

Supply Chain Advantages: Well-established pharmaceutical supply chain China networks with reliable access to raw materials, intermediates, and logistics support for global distribution.

Innovation Capabilities: Strong focus on pharmaceutical innovation China with significant R&D investments in novel formulations, biopharmaceuticals, and advanced manufacturing technologies.


Leading CDMO Companies in China

Top-rated CDMO companies China and pharmaceutical manufacturers China include:

  • Pharmaron (Shaoxing): Premier CDMO services China provider specializing in small molecules, APIs, peptides, and oligonucleotides with extensive process development capabilities. [See CDMO profile]
  • Huiyu (Seacross) Pharma: Established China pharmaceutical manufacturer providing comprehensive CMO/CDMO services for international clients with strong regulatory expertise. [See CDMO profile]
  • CARBOGEN AMCIS Shanghai: Global CDMO with significant pharmaceutical manufacturing China presence offering high-potency API manufacturing and advanced formulation development. [See CDMO profile]
  • Apeloa Pharmaceutical Co: Leading API manufacturer China providing world-class development and manufacturing services for APIs, intermediates, and registered starting materials. [See CDMO profile]
  • SINOWAY INDUSTRIAL CO: Specialized CDMO China provider offering one-stop solutions for APIs and key intermediates with strong technical capabilities. [See CDMO profile]

Related CDMO Information

Leading CDMO Companies in APAC

Leading CDMO Companies in India


Find the Right CDMO Partner in China

Selecting the ideal CDMO China partner requires careful evaluation of technical capabilities, quality systems, regulatory compliance, and cultural alignment. Our network connects you with pre-vetted CDMO companies China that match your specific project requirements and strategic objectives.

Whether you need early-stage development support, clinical trial material manufacturing, or commercial-scale production, we provide expert guidance to navigate the pharmaceutical manufacturing China landscape and establish successful partnerships with leading Chinese CDMOs.

Contact our China CDMO specialists today to identify the perfect manufacturing partner and optimize your pharmaceutical development strategy in China´s dynamic market.